Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies

HLA ◽  
2018 ◽  
Vol 92 ◽  
pp. 34-37 ◽  
Author(s):  
Barbora Kovandova ◽  
Antonij Slavcev ◽  
Zuzana Sekerkova ◽  
Eva Honsova ◽  
Pavel Trunecka
Keyword(s):  
Liver Transplantation ◽  
Antibody Mediated Rejection

SAT-440-Molecular fingerprint of T cell-mediated and antibody-mediated rejection after human liver transplantation

2019 ◽  
Vol 70 (1) ◽  
pp. e830
Author(s):  
Anne Höfer ◽  
Danny Jonigk ◽  
Björn Hartleben ◽  
Robert Geffers ◽  
Murielle Verboom ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
T Cell ◽  
Human Liver ◽  
Molecular Fingerprint ◽  
Antibody Mediated Rejection

Elevation of CD4+ Differentiated Memory T Cells Is Associated With Acute Cellular and Antibody-Mediated Rejection After Liver Transplantation

2013 ◽  
Vol 95 (12) ◽  
pp. 1512-1520 ◽  
Author(s):  
Undine A. Gerlach ◽  
Katrin Vogt ◽  
Stephan Schlickeiser ◽  
Christian Meisel ◽  
Mathias Streitz ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
T Cells ◽  
Memory T Cells ◽  
Antibody Mediated Rejection

scholarly journals Is ABO-Incompatible Living Donor Liver Transplantation Really a Good Alternative for Pediatric Recipients?

Children ◽  
2021 ◽  
Vol 8 (7) ◽  
pp. 600
Author(s):  
Catherine de Magnée ◽  
Louise Brunée ◽  
Roberto Tambucci ◽  
Aurore Pire ◽  
Isabelle Scheers ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Humoral Rejection ◽  
Donor Liver ◽  
Retrospective Case ◽  
Donor Liver Transplantation ◽  
Antibody Mediated Rejection

Background: ABO-incompatible (ABOi) living donor liver transplantation (LDLT) has been proposed to compensate for donor shortage. To date, few studies have reported detailed ABOi LDLT results in large series of pediatric patients. C4d complement deposition in graft capillaries has been reported to be associated with antibody-mediated rejection in solid organ transplantation. Methods: A retrospective case–control study was conducted, comparing clinical outcomes of each of 34 consecutive pediatric ABOi LDLT recipients with those of 2 non-ABOi pairs (n = 68), matched according to pre-transplant diagnostic criteria, age, and date of transplantation. In addition, we studied the C4d immunostaining pattern in 22 ABOi and in 36 non-ABOi recipients whose liver biopsy was performed within the first 4 post-transplant weeks for suspected acute rejection. Results: The incidence of biliary complications was higher in ABOi recipients (p < 0.05), as were the incidence of acute humoral rejection (p < 0.01) and the incidence of retransplantation (p < 0.05). All children who required retransplantation were older than 1 year at the time of ABOi LDLT. Positive C4d immunostaining was observed in 13/22 (59%) ABOi recipients versus 3/36 (8.3%) non-ABOi recipients (p < 0.0001). Conclusions: ABOi LDLT is a feasible option for pediatric end-stage liver disease but carries increased risks for the recipient, especially for children older than 1 year, even with a specific preparation protocol. C4d immunostaining may be a hallmark of acute humoral rejection in ABOi liver transplantation.

scholarly journals A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yingcai Zhang ◽  
Jiebin Zhang ◽  
Huimin Yi ◽  
Jun Zheng ◽  
Jianye Cai ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatic Failure ◽  
Therapeutic Option ◽  
Controlled Trial ◽  
Trial Registration ◽  
Biliary Complications ◽  
Open Label ◽  
Antibody Mediated Rejection ◽  
Link Type ◽  
Induction Strategy

Abstract Background ABO-incompatible liver transplantation (ABO-i LT) has become a rescue therapeutic option for patients with severe hepatic failure. Although the use of rituximab greatly reduces the morbidity of antibody-mediated rejection (AMR), severe adverse effects, such as infection and biliary complications, still seriously threaten the survival of transplant recipients. The aim of this study was to evaluate the safety and feasibility of using mesenchymal stem cells (MSCs) to replace rituximab in ABO-i LT. Methods Twenty-two patients with severe hepatic failure undergoing ABO-i LT were enrolled and randomly divided into two groups: the MSC group and the rituximab group. The safety of the application of MSCs and the incidence of allograft rejection, including antibody-mediated rejection (AMR) and acute cellular rejection (ACR), were evaluated in both groups at the 2-year follow-up period as primary endpoints. Recipients and graft survival and other postoperative complications were compared as secondary endpoints. Results No severe MSC-related adverse events were observed during the trial. MSC treatment yielded comparable, if not better, results than rituximab at decreasing the incidence of acute rejection (9.1% vs 27.3%). Inspiringly, compared to those in the rituximab group, the rates of biliary complications (0% vs 45.5%) and infection (9.1% vs 81.8%) were significantly decreased in the MSC group. In addition, there were no significant differences in 2-year graft and recipient survival between the two groups (81.8% vs 72.7%). Conclusions Our data show that MSC transfusion is comparable to rituximab treatment for AMR prophylaxis following ABO-i LT. Additionally, the results indicate that MSCs are more beneficial to the prevention of infection and biliary complications and may be introduced as a novel immunosuppressive approach for ABO-i LT. Trial registration Trial registration: chictr.org.cn, ChiCTR2000037732. Registered 31 August 2020- Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=57074.

Antibody-Mediated Rejection: Hyperacute Rejection Reality in Liver Transplantation? A Case Report

2008 ◽  
Vol 40 (3) ◽  
pp. 870-871 ◽  
Author(s):  
B. Della-Guardia ◽  
M.D. Almeida ◽  
S.P. Meira-Filho ◽  
M.A. Torres ◽  
F. Venco ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Case Report ◽  
Hyperacute Rejection ◽  
Antibody Mediated Rejection

scholarly journals Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation

2019 ◽  
Vol 5 (10) ◽  
pp. e491 ◽  
Author(s):  
Tetsuya Tajima ◽  
Koichiro Hata ◽  
Hideaki Okajima ◽  
Momoko Nishikori ◽  
Kentaro Yasuchika ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Antibody Mediated Rejection

Antibody-Mediated Rejection after Adult ABO-Incompatible Liver Transplantation Remedied by Gamma-Globulin Bolus Infusion Combined with Plasmapheresis

2004 ◽  
Vol 78 (8) ◽  
pp. 1225-1228 ◽  
Author(s):  
Daisuke Morioka ◽  
Hitoshi Sekido ◽  
Kaori Kubota ◽  
Mitsutaka Sugita ◽  
Kuniya Tanaka ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Gamma Globulin ◽  
Bolus Infusion ◽  
Antibody Mediated Rejection

Bortezomib for Management of Acute Antibody Mediated Rejection Post-Liver Transplantation

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S1252-S1253
Author(s):  
NIkhil Kapila ◽  
Kapil Gupta ◽  
Kawtar Al Khalloufi ◽  
Bobby Zervos
Keyword(s):  
Liver Transplantation ◽  
Antibody Mediated Rejection

scholarly journals Clinical Relevance of Isoagglutinin Rebound in Adult ABO-Incompatible Living Donor Liver Transplantation

2021 ◽  
Vol 11 (12) ◽  
pp. 1300
Author(s):  
Wei-Chen Lee ◽  
Chen-Fang Lee ◽  
Tsung-Han Wu ◽  
Hao-Chien Hung ◽  
Jin-Chiao Lee ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Graft Loss ◽  
Initial Assessment ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Antibody Mediated Rejection ◽  
Group A ◽  
Group B

ABO-incompatible (ABO-I) living donor liver transplantation (LDLT) can be performed successfully. However, anti-ABO isoagglutinin rebound may cause antibody-mediated rejection (AMR) and graft loss. The risk threshold of isoagglutinin rebound is still not defined. 76 ABO-I LDLT recipients were divided into group A (n = 56) with low isoagglutinin titers (<1:256), and group B (n = 20) with high isoagglutinin titers (≥1:256), at initial assessment for liver transplantation. The last 12 patients in group B received a modified desensitization regimen by adding bortezomib to deplete plasma cells. Six (10.7%) patients in group A and 10 (50.0%) patients in group B had postoperative isoagglutinin rebound (p < 0.001). Three patients (5.54%) in group A and two patients (10%) in group B developed clinical AMR (p = 0.602). The cutoff value of postoperative isoagglutinin rebound to cause clinical AMR was ≥1:1024. Among the 12 patients in group B with bortezomib administration, isoagglutinin rebounded up to 1:128 only, and no clinical AMR occurred. In conclusion, the patients with high isoagglutinin titers had a higher rate of postoperative isoagglutinin rebound. Isoagglutinin rebound ≥1:1024 is risky for developing clinical AMR. Adding bortezomib into the desensitization regimen may mitigate isoagglutinin rebound, and avoid clinical AMR.

Sign in / Sign up

Export Citation Format

Share Document